title: Comparison between patients with IgA nephropathy with minimal change disease and patients with minimal change disease.
abstract: OBJECTIVE
  To compare the clinicopathological characteristics, treatment response, and prognosis between patients with IgAN nephropathy with minimal change disease (MCD-IgAN) and patients with minimal change disease (MCD).
  
  
  METHODS
  77 patients with biopsy-proven MCD-IgAN from the Jinling Hospital IgAN Registry and 77 patients with MCD followed up for ≥ 3 years were retrospectively reviewed.
  
  
  RESULTS
  MCD-IgAN and MCD patients had similar clinical presentations, both were predominantly young males, the disease mainly manifested as nephrotic syndrome, and the patients rarely presented with microscopic hematuria. Compared with the MCD group, patients with MCD-IgAN had lower levels of baseline serum albumin (p < 0.01) and eGFR (p < 0.05), a higher level of urine n-acetylglucosaminidase (p < 0.01), higher proportion of mesangial hypercellularity (M1), and more severe acute tubulointerstitial lesions in renal pathology (p < 0.01, p < 0.01, respectively). After 8 weeks of corticosteroid therapy, no significant differences were observed in the rate of complete remission, partial remission, and no remission between MCDIgAN and MCD patients (88.3% vs. 90.9%, 10.4% vs. 5.2%, 1.3% vs. 3.9%, p > 0.05). The median time to achieve remission was 4 weeks (range 1 - 24 weeks) and 4 weeks (range 1 - 28 weeks), respectively. No significant difference existed in the efficacy of corticosteroid between the two groups. During 3.96 years (range 3.0 - 8.5 years) of follow-up, no patients in the two groups entered end-stage renal disease (ESRD), only 2 patients (2.6%) with MCD-IgAN had > 50% reduction of eGFR.
  
  
  CONCLUSIONS
  MCD-IgAN may be controlled well achieving a comparable clinical outcome as MCD but more frequently necessitates additional immunosuppressive medication.
authors.forename: Xiao-Wei
authors.initials: XW
authors.lastname: Li
authors.forename: Shui-Qin
authors.initials: SQ
authors.lastname: Cheng
authors.forename: Shao-Shan
authors.initials: SS
authors.lastname: Liang
authors.forename: Wei-Bo
authors.initials: WB
authors.lastname: Le
authors.forename: Cai-Hong
authors.initials: CH
authors.lastname: Zeng
authors.forename: Jin-Quan
authors.initials: JQ
authors.lastname: Wang
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Liu
mesh_terms: D000118:Acetylglucosaminidase / Q000652:urine; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D009402:Nephrosis, Lipoid / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D009404:Nephrotic Syndrome / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D012709:Serum Albumin; D000118:Acetylglucosaminidase